Uprifosbuvir
id:
uprifosbuvir-293-15941920
title:
Uprifosbuvir
text:
Uprifosbuvir (MK-3682) is an antiviral drug developed for the treatment of hepatitis C. It is a nucleotide analogue which acts as an NS5B RNA polymerase inhibitor. As of 2019 it was in Phase III human clinical trials. In 2017 owner Merck wrote down the value of uprifosbuvir to US$240 million, for a write-down of $2.9 billion, reducing its earnings per share from 42¢ to a loss of 22¢ for the fourth quarter of 2016. This was attributed to the hepatitis C drug market rather than uprifosbuvir itself
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Uprifosbuvir
date created:
date modified:
2024-03-23T09:39:36Z
main entity:
{"identifier":"Q27281714","url":"https://www.wikidata.org/entity/Q27281714"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/d/d8/Uprifosbuvir_structure.svg","width":512,"height":250}
fields total:
13
integrity:
15